Future imperfect for Quintiles?
Future imperfect for Quintiles?
Miller, Jim
Pharmaceutical Technology Europe
Following the rejection of Dennis Gillings' offer to buy back Quintiles, the company is looking at alternative strategies to ensure that it remains independent and publicly owned. In the biotech sector, a funding drought could lead to more problems for R&D-based CROs and the threat of future job losses.
Welcome to my first column for Contract Services Europe (CSE). Although I have been writing a column for Pharmaceutical Technology North America and its sister publication, BioPharm, for several years, when Kevin Robinson invited me to address the European pharmaceutical ...
Read the Full Article, Get a FREE Trial for instant access ?
Comments: 0